Shopping Cart
Remove All
Your shopping cart is currently empty
Naxitamab
😃Good
Catalog No. T77448Cas No. 1879925-92-4
Alias Naxitamab-gqgk, Humanized 3F8, Hu3F8
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.
Naxitamab
Naxitamab
😃Good
Catalog No. T77448Alias Naxitamab-gqgk, Humanized 3F8, Hu3F8Cas No. 1879925-92-4
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $189 | In Stock | In Stock | |
| 5 mg | $476 | In Stock | In Stock | |
| 10 mg | $788 | - | In Stock | |
| 25 mg | $1,180 | - | In Stock | |
| 50 mg | $1,590 | - | In Stock | |
| 100 mg | $2,130 | - | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:100% (SEC-HPLC)
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting GD2 with antitumor activity, used to study neuroblastoma, osteosarcoma, and other GD2-positive cancers. |
| Targets&IC50 | LAN1:5.1 μg/mL |
| In vitro | Naxitamab (Hu3F8; 72 h) exhibits cytotoxicity against the neuroblastoma cell line LAN-1, with an EC50 value of 5.1 μg/mL[1]. Naxitamab (0.1-1 μg/mL; 4 h; peripheral blood mononuclear cells (PBMC) and polymorphonuclear leukocytes (PMN)) demonstrates antibody-dependent cell-mediated cytotoxic effects (ADCC)[1]. |
| In vivo | In athymic nude mice with LAN-1 xenografts, Naxitamab (Hu3F8; 100 mg/kg; intravenous; twice a week for 4 weeks) inhibits tumor growth in neuroblastoma xenografts[1]. |
| Synonyms | Naxitamab-gqgk, Humanized 3F8, Hu3F8 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | GD2 |
| Molecular Weight | 144.38 kDa |
| Cas No. | 1879925-92-4 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy Naxitamab | purchase Naxitamab | Naxitamab cost | order Naxitamab | Naxitamab in vivo | Naxitamab in vitro | Naxitamab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.